Priority Medicines for Europe and the World 2013 Update. Background Paper 7 - Cross-cutting Themes. BP 7.1 - Priority Medicines for Children
(2013; 243 pages)

Abstract

Children are entitled to safe, efficacious, and age-appropriate medicines. However, the provision of optimal medicines for children is limited by the lack of commercial incentives, a dearth of clinical trials on paediatric medicines, delays in licensing medicines for children, and the absence of suitable formulations for children. Children are not small adults, but rather a vulnerable population with specific needs resulting from their changing physiology, who make up a heterogeneous patient group with a scope of diseases different than those of adults, and for whom there is a scarcity of data on appropriate medicines delivery and use. Therefore, these needs are discussed in detail in this background paper; the challenges and opportunities for improvement and further research are also identified.

 
The WHO Essential Medicines and Health Products Information Portal was designed and is maintained by Human Info NGO. Last updated: August 29, 2014